Kura Oncology to Announce Q2 2024 Financial Results

SAN DIEGO, Aug. 01, 2024 – Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical enterprise focused on precision medicines for cancer treatment, announced plans to release its second quarter 2024 financial results post-market close on Thursday, August 8, 2024. Kura’s management will conduct a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to present the financial outcomes and provide a corporate update. Interested parties can join the live call by dialing (877) 300-8521 for domestic participants and (412) 317-6026 for international participants. A live and archived webcast of the event will be available online in the investor relations section of Kura’s website.

Kura Oncology is dedicated to developing precision medicines for cancer treatment. The company’s portfolio features small molecule drug candidates designed to target cancer signaling pathways. One of its key candidates, Ziftomenib, is an oral, once-daily drug targeting the menin-KMT2A protein interaction. Ziftomenib has received Breakthrough Therapy Designation for treating relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has finished enrolling participants in a Phase 2 registration-directed trial (KOMET-001) for this drug in R/R NPM1-mutant AML. Additionally, Kura is conducting various clinical trials to assess the efficacy of Ziftomenib combined with current standard treatments in both newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML.

Another prominent candidate in Kura’s pipeline is Tipifarnib, a selective farnesyl transferase inhibitor (FTI). Tipifarnib is currently being tested in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also investigating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as both a monotherapy and in combination with other targeted therapies (FIT-001).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!